ALNYLAM PHARMACEUTICALS Patent applications |
Patent application number | Title | Published |
20110282044 | PROCESS FOR SYNTHESIZING OLIGONUCLEOTIDE PHOSPHATE DERIVATIVES - The present invention describes simple, efficient, and enzyme-free method of making oligonucleotide phosphate derivatives. This invention presents novel process using automated synthesizer for synthesizing oligonucleotide phosphate derivatives using a diaryl phosphonate as reagent. | 11-17-2011 |
20110201798 | THERAPEUTIC COMPOSITIONS - This application relates to therapeutic siRNA agents and methods of making and using the agents. | 08-18-2011 |
20110117125 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS - The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. | 05-19-2011 |
20110065774 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF - This invention relates generally to chemically oligonucleotides (e.g., modified oligonucleotides) useful for augmenting activity of a target gene. | 03-17-2011 |
20110054160 | THERAPEUTIC COMPOSITIONS - This application relates to therapeutic siRNA agents and methods of making and using the agents. | 03-03-2011 |
20100292455 | MODIFIED iRNA AGENTS - The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents. | 11-18-2010 |
20100280102 | DOUBLE-STRANDED RIBONUCLEIC ACID WITH INCREASED EFFECTIVENESS IN AN ORGANISM - The present invention relates to a method for the targeted selection of a double-stranded ribonucleic acid (dsRNA) consisting of two single strands that exhibits increased effectiveness in inhibiting the expression of a target gene by means of RNA interference, wherein at least end of the dsRNA comprises a nucleotide overhang of 1 to 4 unpaired nucleotides in length; wherein the unpaired nucleotide adjacent to the terminal nucleotide pair comprises a purine base; and wherein the terminal nucleotide pair on both ends of the dsRNA is a G-C pair, or at least two of the last four consecutive terminal nucleotide pairs are G-C pairs. | 11-04-2010 |
20100222417 | Compostions and methods for enhancing oligonucleotide delivery across and into epithelial tissues - The present invention relates to the delivery of oligonucleotide across and into epithelial tissues by conjugating the oligonucleotide with a lipophile and/or coadministering with a penetration enhancer. In particular, the present invention provides a composition comprising a conjugated siRNA, which are advantageous for the in vivo delivery of nucleic acids across and into epithelial tissue. Additionally, the present invention provides methods of improving delivery of oligonucleotides across the epithelial tissues with the aid of a mechanical enhancer. | 09-02-2010 |
20100179309 | MODIFIED iRNA AGENTS - The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a carbohydrate; or a steroid, e.g., cholesterol, which is optionally substituted with at least one carbohydrate. is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents. | 07-15-2010 |